查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984037

真菌感染疾病诊断市场：依诊断技术、病原体类型、检体类型、感染疾病类型、检测模式和最终用户划分－2026-2032年全球市场预测

Fungal Infections Diagnosis Market by Diagnostic Technology, Pathogen Type, Specimen Type, Infection Type, Testing Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，真菌感染疾病诊断市场价值将达到 98.4 亿美元，到 2026 年将成长至 105.2 亿美元，到 2032 年将达到 158.5 亿美元，复合年增长率为 7.04%。

主要市场统计数据
基准年 2025 98.4亿美元
预计年份：2026年 105.2亿美元
预测年份：2032年 158.5亿美元
复合年增长率 (%) 7.04%

现代真菌感染疾病诊断概论：临床负担、诊断挑战以及对更快更准确检测的需求

真菌感染疾病的临床和诊疗紧迫性，因其在各种医疗环境中诊断的复杂性而更加凸显。临床医生面临的持续挑战是，真菌感染疾病的症状通常与细菌和病毒感染相似，但所需的治疗策略却截然不同。诊断的延误和不准确会直接导致患者预后不良、住院时间延长以及抗生素抗药性风险增加，所有这些都凸显了更快、更准确诊断的重要性。

分子医学、蛋白质体学、自动化、照护现场技术的进步以及数据驱动的临床整合，推动了真菌感染疾病诊断领域的变革性变化。

随着技术、营运和资料中心要素的融合，真菌感染疾病诊断领域正经历变革性的转变。分子诊断加速了从表型鑑定到基因型和序列表征的转变，不仅能够快速检测病原体，还能提供更丰富的抗药性决定因素和菌株层级突变资讯。同时，MALDI-TOF MS等质谱技术透过缩短鑑定时间和减少技术人员的工作时间，重新定义了检查室工作流程。此外，显微镜和培养工作流程的改进也持续提供重要的确诊和药敏试验数据。

评估 2025 年美国关税对全球真菌感染疾病诊断供应链、采购经济和创新轨蹟的累积影响。

关税等政策会对整个诊断供应链、采购流程和创新生态系统产生广泛且有时被低估的连锁反应。 2025年，美国对某些进口商品征收的关税影响了真菌检测流程中必不可少的诊断设备、耗材和试剂的成本结构。对于依赖全球供应商网路的临床检查室和医院系统而言，不断上涨的进口成本正在影响其采购决策，并加速其供应商关係多元化的进程。

为了指导策略优先排序，我们将诊断技术、最终用户、检体类型、病原体概况和测试模式等关键细分见解整合起来。

了解市场需要对诊断技术进行详细分析，并了解每种方法如何满足临床应用需求和检查室操作。基于培养的方法仍然是许多检查室的临床基础，液体和固体培养基培养可透过生长和抗真菌药物敏感性试验提供确诊机会。免疫检测，包括酵素连结免疫吸附试验 (ELISA) 平台和横向流动化验，能够检测抗原和抗体，支持快速临床分流和监测，尤其是在资源有限的环境和照护现场(POC) 环境中。基质辅助雷射解吸电离飞行时间质谱 (MALDI-TOF MS) 可显着减少鑑定培养分离株所需的时间和精力，从而加快后续临床决策。显微镜检查在许多医疗机构中仍然是快速初步诊断的关键，尤其是在形态学观察可立即用于选择适当治疗方法的情况下。分子诊断包括次世代定序 (NGS) 和聚合酵素链锁反应(PCR) 方法。在新一代定序（NGS）领域，Illumina和Ion Torrent定序技术在读取准确性、通量和执行时间方面各有优势，能够实现全面的病原体分析和集体爆发分析。在聚合酵素链锁反应（PCR）领域，传统PCR和即时聚合酵素链锁反应能够在既定的临床工作流程中实现标靶和高灵敏度的检测。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和竞争格局：重点关注采用、监管和容量趋势。

区域趋势既影响技术采纳的速度，也影响诊断服务所提供的结构。在美洲，高通量参考实验室和综合医疗保健系统推动了对高通量平台和整合工作流程的需求，而强大的临床研究网络则支援定序和质谱检验管道的建立和早期应用。然而，复杂的报销机制和区域采购模式要求必须清楚证明其临床效用和成本效益，才能支持其在三级医疗机构以外的广泛应用。

影响真菌感染疾病诊断生态系统的主要企业的企业趋势和策略，包括创新途径、伙伴关係和商业化策略。

竞争格局由成熟的仪器和试剂製造商、专业的分子诊断和测序平台提供者、合约研究组织 (CRO) 以及新兴的软体数据分析公司组成。市场领导者透过整合强大的仪器平台、检验的耗材、软体驱动的工作流程优化以及能够减轻客户检验负担的服务合约来脱颖而出。中型公司通常透过针对特定检测领域、照护现场配置或针对特定检查室领域量身定制的高性价比耗材模式来与之竞争。

为产业领导者提供切实可行的建议，以加速临床部署、加强供应链、优化产品组合，并在整个诊断领域中获得价值。

产业领导者应优先采取一系列策略措施，在控制营运风险的同时，加速临床应用。首先，投资进行有针对性的临床效用研究，将诊断结果与可操作的治疗决策和可衡量的患者疗效联繫起来。强而有力的临床证据能够降低支付方的抵触情绪，并推动更广泛的应用。其次，实现供应链多元化，考虑区域性生产和策略性库存缓衝，以降低关税和物流风险，并确保即使在政策变更期间也能持续提供检测服务。

调查方法，包括一级和二级调查方法、资料检验、检验通讯协定以及分析的根本限制。

本分析采用混合研究方法，将一手质性检验与二手证据的系统性回顾和三角验证结合。一手研究包括对临床实验室技术人员、医院采购经理、研究机构研究人员和行业高管进行结构化访谈，以收集有关工作流程、检验障碍和推广驱动因素的经验性见解。二手研究包括同行评审文献、监管指导文件、临床实践指南和技术白皮书，用于为一手研究结果提供背景资讯并检验分析假设。

为了了解真菌感染疾病诊断的演变趋势，本书提出简洁的结论，为临床医生、实验室管理者、投资者和政策制定者提供见解。

真菌感染疾病的诊断正在经历重大变革时期，技术创新、供应链重组和实证实践的结合正在重塑临床格局。检查室和医疗机构面临复杂的抉择，必须在分析绩效、营运实际情况和支付方期望之间取得平衡。随着分子诊断和蛋白质组学平台日益成熟，照护现场检测（POC​​）也日益普及，那些能够无缝整合到现有工作流程中并展现出切实临床疗效的解决方案更有可能获得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：真菌感染疾病诊断市场：依诊断技术划分

  • 培养方法
    • 液体培养基
    • 固体培养基培养
  • 免疫检测
    • ELISA
    • 横向流动化验
  • MALDI-TOF-MS
  • 显微镜检查
  • 分子诊断
    • 下一代定序
      • Illumina定序
      • 离子洪流序列
    • 聚合酵素链锁反应
      • 常规聚合酵素链锁反应
      • 即时聚合酵素链锁反应

第九章：真菌感染疾病诊断市场：依病原体类型划分

  • 曲菌症
  • 念珠菌症
  • 隐球菌病
  • 皮肤丝状菌症
  • 白霉菌症

第十章：霉菌感染疾病诊断市场：依检体类型划分

  • 血
  • 脑脊髓液
  • 痰
  • 组织
  • 尿

第十一章：真菌感染疾病诊断市场：按感染类型划分

  • 表层真菌病
  • 皮下真菌病
  • 侵袭性真菌病
  • 机会性真菌病
  • 地方性真菌病

第十二章：真菌感染疾病诊断市场：依检测模式划分

  • 临床试验
  • 就地检验
  • 仅供研究使用

第十三章：真菌感染疾病诊断市场：依最终用户划分

  • 诊断实验室
  • 医院和诊所
  • 研究机构

第十四章：真菌感染疾病诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：真菌感染疾病诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：真菌感染疾病诊断市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国真菌感染疾病诊断市场

第十八章：中国真菌感染疾病诊断市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Associates of Cape COD, Inc. by Seikagaku Group company
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche AG
  • FUJIFILM Wako Pure Chemical Corporation
  • Genobio Pharmaceutical Co., Ltd.
  • Hologic, Inc.
  • IMMY
  • InBios International, Inc.
  • Labcorp Holdings Inc.
  • Merck KGaA
  • MicroGen Diagnostics, LLC+
  • MiraVista Diagnostics, LLC
  • Norgen BIoTek Corp.
  • PathoNostics BV
  • Polysciences, Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Seegene Inc.
  • Siemens Healthineers
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific Inc.
  • Xiamen Bioendo Technology Co., Ltd.
  • Zhuhai DL BIoTech Co., Ltd.
Product Code: MRR-346757DFA1E9

The Fungal Infections Diagnosis Market was valued at USD 9.84 billion in 2025 and is projected to grow to USD 10.52 billion in 2026, with a CAGR of 7.04%, reaching USD 15.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.84 billion
Estimated Year [2026] USD 10.52 billion
Forecast Year [2032] USD 15.85 billion
CAGR (%) 7.04%

Comprehensive introduction to contemporary fungal diagnostics, framing clinical burdens, diagnostic gaps, and the imperative for faster, more precise detection

The clinical and operational urgency around fungal infections has intensified as these pathogens continue to present diagnostic complexity across diverse care settings. Clinicians face a persistent challenge: fungal disease often mimics bacterial and viral syndromes while requiring fundamentally different therapeutic strategies. Delays or inaccuracies in diagnosis translate directly into adverse patient outcomes, extended hospital stays, and amplified antimicrobial resistance risks, which together raise the stakes for faster and more precise diagnostics.

Against this backdrop, diagnostic stakeholders are navigating a rapidly evolving toolkit that spans traditional culture methods to advanced molecular and proteomic platforms. Laboratories and hospitals are balancing the reliability of culture-based approaches with the speed advantages of molecular diagnostics and the throughput benefits of mass spectrometry technologies. At the same time, point-of-care testing is emerging as a complement to centralized workflows, particularly in outpatient and resource-limited environments where rapid decision-making is critical.

As diagnostic technologies diversify, decision-makers must weigh analytical performance, clinical utility, throughput, and cost within constrained budgets and complex reimbursement landscapes. Clinical laboratories, research institutes, and hospital networks are therefore prioritizing adoption pathways that align with institutional capabilities and patient populations. This introduction frames the subsequent analysis by highlighting the clinical imperatives, technology trade-offs, and operational considerations that will shape near-term investment and policy choices in fungal diagnostics.

Transformative shifts in fungal diagnostic landscape driven by molecular advances, proteomics, automation, point-of-care evolution, and data-driven clinical integration

The landscape of fungal diagnostics is undergoing transformative shifts driven by converging technological, operational, and data-centric forces. Molecular diagnostics have accelerated the move from phenotype-based identification toward genotypic and sequence-based characterization, enabling not only quicker pathogen detection but also richer information about resistance determinants and strain-level variation. Concurrently, mass spectrometry technologies such as MALDI TOF MS have redefined laboratory workflows by compressing identification timelines and reducing hands-on technician time, while improvements in microscopy and culture workflows continue to provide essential confirmatory and susceptibility data.

Beyond assay performance, automation and laboratory informatics are centralizing data flows and enabling more consistent workflows across decentralized laboratory networks. Integration of laboratory information systems with clinical decision support is improving result interpretation and driving more actionable reporting, thereby shortening the time from detection to therapy optimization. In parallel, the maturation of point-of-care modalities and lateral flow immunoassays is expanding diagnostic reach into outpatient clinics and emergency departments, where immediate results can drive timely antifungal stewardship decisions.

Advances in sequencing, particularly in Next Generation Sequencing methodologies, are unlocking new capabilities for comprehensive pathogen profiling and outbreak investigation. Improvements in NGS chemistry, platform accessibility, and bioinformatics pipelines are making deep sequencing feasible for diagnostic laboratories seeking to characterize complex infections or mixed populations. At the same time, real-time PCR and conventional PCR remain indispensable for targeted, rapid detection when clinical questions are narrow and turnaround time is critical.

Finally, the integration of digital health tools and artificial intelligence into fungal diagnostics is beginning to influence image-based interpretation, predictive risk stratification, and workflow optimization. Together, these shifts are not incremental; they represent a reconfiguration of diagnostic pathways, where speed, specificity, and integrated data outputs will increasingly determine clinical adoption and laboratory investment priorities.

Assessing the cumulative impact of United States tariffs in 2025 on global fungal diagnostics supply chains, procurement economics, and innovation trajectories

Policy instruments such as tariffs can have broad and sometimes underappreciated ripple effects across diagnostic supply chains, procurement practices, and innovation ecosystems. In 2025, United States tariffs introduced on selected imports are influencing cost structures for diagnostic instruments, consumables, and reagents that are integral to fungal testing workflows. For clinical laboratories and hospital systems that rely on global supplier networks, incremental import costs are shaping purchasing decisions and accelerating efforts to diversify vendor relationships.

Procurement teams are responding by recalibrating supplier mixes, increasing order consolidation where possible, and exploring domestic manufacturers for critical components to mitigate exposure to tariff-driven price volatility. These adaptations carry operational implications: validated alternative suppliers require requalification, and product substitutions can affect workflow efficiency and diagnostic continuity. In research settings, higher reagent costs are complicating study design and budget planning, which in turn can slow translational research efforts and delay the generation of clinical validation data that underpins adoption.

Tariffs are also influencing innovation strategies among manufacturers. Some vendors are reshaping supply chains through near-shoring and localized manufacturing investments to preserve competitive pricing while maintaining product availability. Others are accelerating product portfolios toward consumable-efficient platforms or integrated systems that reduce dependency on high-tariff components. From a market perspective, these shifts may alter the pace at which laboratories upgrade to next-generation platforms, and they may reshape negotiations between customers and suppliers around volume-based pricing and multi-year service agreements.

Importantly, regulatory and reimbursement frameworks interact with tariff impacts. Healthcare payers and hospitals may be slower to approve higher-cost diagnostics absent clear evidence of improved clinical outcomes, which places a premium on robust clinical utility studies. In summary, tariffs are prompting a multi-dimensional response that spans procurement, validation, manufacturing strategy, and evidence generation, and stakeholders that proactively adapt their supply chain and clinical evidence strategies will be better positioned to sustain service quality and innovation momentum.

Key segmentation insights synthesizing diagnostic technologies, end users, specimen types, pathogen profiles, and testing modes to guide strategic prioritization

Understanding the market requires a granular view of diagnostic technologies and how each modality maps to clinical use cases and laboratory operations. Culture Based approaches remain the clinical backbone for many laboratories, with liquid broth culture and solid media culture providing growth-based confirmation and the opportunity for antifungal susceptibility testing. Immunoassays, including Elisa platforms and lateral flow assay formats, deliver antigen and antibody detection that supports rapid clinical triage and surveillance, particularly in resource-constrained or point-of-care settings. MALDI TOF MS has materially lowered time-to-identification for cultured isolates, reducing labor and accelerating downstream clinical decision-making. Microscopy continues to be indispensable for rapid presumptive diagnosis in many care environments, particularly when morphology informs immediate therapeutic choices. Molecular Diagnostics encompass both Next Generation Sequencing and Polymerase Chain Reaction based approaches. Within NGS, Illumina Sequencing and Ion Torrent Sequencing offer complementary trade-offs between read accuracy, throughput, and run time, enabling comprehensive pathogen profiling and outbreak analytics. Within PCR, Conventional Polymerase Chain Reaction and Real Time Polymerase Chain Reaction provide targeted, highly sensitive detection with well-established clinical workflows.

End users include Diagnostic Laboratories, Hospitals & Clinics, and Research Institutes, each with distinct drivers for technology adoption and investment. Diagnostic laboratories prioritize platforms that balance throughput, cost-per-test, and integration with laboratory information systems, while hospitals and clinics often favor rapid-turnaround modalities that can directly influence patient management. Research institutes focus on depth of characterization and flexibility for exploratory assays, often serving as early adopters for advanced sequencing and proteomic methods.

Specimen types such as blood, cerebrospinal fluid, sputum, tissue, and urine frame analytical requirements and pre-analytical workflows. Blood and cerebrospinal fluid demand assays with high analytical sensitivity and contamination control given the clinical severity of bloodstream and central nervous system infections. Respiratory specimens like sputum and tissue samples introduce complexity in sample processing and often benefit from combined culture and molecular workflows. Urine-based testing, while less common for invasive disease, is valuable in certain surveillance and outpatient contexts.

Pathogen-type segmentation-including Aspergillosis, Candidiasis, Cryptococcosis, Dermatophytosis, and Mucormycosis-drives diagnostic target selection, as each genus and clinical syndrome has different analytic challenges, resistance profiles, and specimen preferences. Testing modes span Laboratory Testing, Point Of Care Testing, and Research Use Only applications, reflecting the spectrum from clinically actionable diagnostics to exploratory and investigational assays. Taken together, these segmentation dimensions inform strategic prioritization for technology development, regulatory planning, and commercialization pathways, as trade-offs between sensitivity, speed, and operational fit differ across each segment and user class.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption, regulation, and capacity trends

Regional dynamics shape both the pace of technology adoption and the structure of diagnostic service delivery. In the Americas, high-capacity reference laboratories and integrated health systems drive demand for high-throughput platforms and consolidated workflows, while strong clinical research networks support pathway validation and early adoption of sequencing and mass spectrometry. Reimbursement complexity and regional procurement models, however, require clear demonstration of clinical utility and cost-effectiveness to support widespread deployment beyond tertiary centers.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure results in a dual market pattern: advanced laboratories in urban centers and tertiary hospitals adopt cutting-edge molecular and proteomic platforms, while many settings continue to rely on robust culture and immunoassay workflows. Regulatory harmonization efforts in parts of Europe facilitate cross-border adoption, but diverse reimbursement landscapes and variable laboratory capacity in the broader region necessitate adaptable product designs and targeted implementation support.

In Asia-Pacific, rapid investments in laboratory capacity and a growing focus on infectious disease preparedness are creating fertile conditions for both centralized and decentralized diagnostics. Market dynamics in this region are influenced by a mix of large public health procurements and private sector laboratory expansion, offering opportunities for manufacturers that can scale supply and provide training and validation support. Across all regions, local manufacturing, supply chain resilience, and regulatory alignment are increasingly decisive factors that affect procurement cycles and the speed at which new technologies are integrated into routine practice.

Corporate intelligence and key company strategies shaping the fungal diagnostics ecosystem including innovation pathways, partnerships, and commercialization playbooks

The competitive landscape is characterized by a mix of established instrument and reagent manufacturers, specialized molecular and sequencing platform providers, contract research organizations, and emergent software and data analytics firms. Market leaders are differentiating through integrated solutions that combine robust instrument platforms with validated consumables, software-enabled workflow orchestration, and service agreements that reduce customer validation burdens. Mid-tier players often compete on niche assays, point-of-care formats, or cost-effective consumable models that fit specific laboratory segments.

Strategic collaborations and distribution partnerships are common, enabling companies to extend geographic reach and couple complementary technologies-such as linking a mass spectrometry identification system with a molecular resistance assay. Additionally, start-ups are introducing focused innovations in areas such as simplified sample preparation, rapid lateral flow formats with enhanced sensitivity, and bioinformatics tools that streamline NGS interpretation. Contract laboratories and reference testing networks play a pivotal role as early adopters and validators, providing pathways for new technologies to demonstrate clinical utility and drive broader laboratory adoption.

A clear pattern emerges where companies that invest in evidence generation, regulatory preparedness, and scalable service models are better positioned to secure long-term contracts with health systems. Moreover, firms that can offer training, remote support, and integration with laboratory information systems reduce friction for customers and accelerate uptake. Competitive advantage increasingly hinges on the ability to deliver end-to-end solutions that address analytical performance, operational efficiency, and the practical realities of laboratory validation and clinician adoption.

Actionable recommendations for industry leaders to accelerate clinical adoption, fortify supply chains, optimize portfolios, and capture value across diagnostic segments

Industry leaders should prioritize a set of strategic actions that accelerate clinical adoption while managing operational risks. First, invest in targeted clinical utility studies that link diagnostic outputs to actionable treatment decisions and measurable patient outcomes; robust clinical evidence reduces payer resistance and supports broader uptake. Second, diversify supply chains and consider regional manufacturing or strategic inventory buffering to mitigate tariff and logistics risks, ensuring continuity of testing services during policy-driven disruptions.

Third, align product development with end-user workflows by offering modular platforms that support both high-throughput centralized testing and rapid point-of-care use cases. This approach increases addressable use cases while allowing laboratories to scale adoption according to capacity. Fourth, strengthen partnerships with reference laboratories and clinical networks to facilitate third-party validation, early use-case documentation, and clinician education that can accelerate adoption curves. Fifth, embed software-driven value propositions-such as connectivity, result interpretation, and workflow automation-into offerings to reduce laboratory burden and improve result utility for clinicians.

Finally, engage proactively with regulatory bodies and payers to clarify evidence expectations and reimbursement pathways early in development. By anticipating regulatory and reimbursement questions and incorporating real-world evidence collection into rollouts, companies can shorten time-to-market and reduce adoption friction. These actions, taken together, create a resilient commercial strategy that balances innovation, evidence generation, and operational continuity.

Transparent research methodology outlining primary and secondary research approaches, data triangulation, validation protocols, and limitations informing the analysis

The analysis is founded on a mixed-methods research approach that integrates primary qualitative inquiry with systematic secondary evidence review and triangulation. Primary research included structured interviews with clinical laboratorians, hospital procurement leaders, research institute investigators, and industry executives to capture experiential insights into workflows, validation barriers, and adoption drivers. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and technology white papers to contextualize primary findings and to verify analytical assumptions.

Data triangulation was employed to reconcile disparate inputs and to identify consistent patterns across stakeholder groups and evidence sources. Technology mapping and capability assessments were performed to align platform characteristics with clinical use cases and laboratory operational constraints. Additionally, a review of clinical trial registries and patent filings informed the forward-looking view on innovation trajectories and emerging assay modalities.

The research recognizes limitations inherent to qualitative and secondary data, including variability in regional reporting, evolving regulatory landscapes, and the lag between technological development and published clinical validation. To mitigate these limitations, the analysis emphasizes corroborated themes and distinguishes between observed practice and aspirational capabilities. Where appropriate, sensitivity to regional heterogeneity and institutional capacity has been maintained to ensure that recommendations are actionable across diverse healthcare contexts.

Concise conclusion synthesizing implications for clinicians, laboratory leaders, investors, and policymakers to navigate the evolving fungal diagnostics landscape

Fungal diagnostics are in a period of substantive evolution where technological innovation, supply chain realignment, and evidence-driven adoption converge to reshape clinical practice. Laboratories and healthcare organizations face a complex landscape of choices that must balance analytical performance with operational realities and payer expectations. As molecular and proteomic platforms mature and point-of-care modalities broaden access, success will favor solutions that demonstrate tangible clinical impact while integrating smoothly into existing workflows.

Policy and procurement variables, such as tariffs and regional manufacturing dynamics, will continue to influence investment and adoption patterns. Stakeholders that proactively address these factors through diversified sourcing, strategic partnerships, and focused evidence generation will preserve continuity of diagnostic services and accelerate innovation uptake. Ultimately, sustained progress will depend on collaborative approaches that link manufacturers, clinical leaders, and health systems in shared efforts to validate, implement, and optimize diagnostic pathways for fungal disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fungal Infections Diagnosis Market, by Diagnostic Technology

  • 8.1. Culture Based
    • 8.1.1. Liquid Broth Culture
    • 8.1.2. Solid Media Culture
  • 8.2. Immunoassays
    • 8.2.1. Elisa
    • 8.2.2. Lateral Flow Assay
  • 8.3. MALDI TOF MS
  • 8.4. Microscopy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Next Generation Sequencing
      • 8.5.1.1. Illumina Sequencing
      • 8.5.1.2. Ion Torrent Sequencing
    • 8.5.2. Polymerase Chain Reaction
      • 8.5.2.1. Conventional Polymerase Chain Reaction
      • 8.5.2.2. Real Time Polymerase Chain Reaction

9. Fungal Infections Diagnosis Market, by Pathogen Type

  • 9.1. Aspergillosis
  • 9.2. Candidiasis
  • 9.3. Cryptococcosis
  • 9.4. Dermatophytosis
  • 9.5. Mucormycosis

10. Fungal Infections Diagnosis Market, by Specimen Type

  • 10.1. Blood
  • 10.2. Cerebrospinal Fluid
  • 10.3. Sputum
  • 10.4. Tissue
  • 10.5. Urine

11. Fungal Infections Diagnosis Market, by Infection Type

  • 11.1. Superficial Mycoses
  • 11.2. Subcutaneous Mycoses
  • 11.3. Invasive Mycoses
  • 11.4. Opportunistic Mycoses
  • 11.5. Endemic Mycoses

12. Fungal Infections Diagnosis Market, by Testing Mode

  • 12.1. Laboratory Testing
  • 12.2. Point Of Care Testing
  • 12.3. Research Use Only

13. Fungal Infections Diagnosis Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals & Clinics
  • 13.3. Research Institutes

14. Fungal Infections Diagnosis Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Fungal Infections Diagnosis Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Fungal Infections Diagnosis Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Fungal Infections Diagnosis Market

18. China Fungal Infections Diagnosis Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. Associates of Cape COD, Inc. by Seikagaku Group company
  • 19.7. Becton, Dickinson and Company
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. BioMerieux SA
  • 19.10. Bruker Corporation
  • 19.11. Danaher Corporation
  • 19.12. DiaSorin S.p.A.
  • 19.13. Eurofins Viracor, LLC
  • 19.14. F. Hoffmann-La Roche AG
  • 19.15. FUJIFILM Wako Pure Chemical Corporation
  • 19.16. Genobio Pharmaceutical Co., Ltd.
  • 19.17. Hologic, Inc.
  • 19.18. IMMY
  • 19.19. InBios International, Inc.
  • 19.20. Labcorp Holdings Inc.,
  • 19.21. Merck KGaA
  • 19.22. MicroGen Diagnostics, LLC+
  • 19.23. MiraVista Diagnostics, LLC
  • 19.24. Norgen Biotek Corp.
  • 19.25. PathoNostics B.V.
  • 19.26. Polysciences, Inc.
  • 19.27. Qiagen N.V.
  • 19.28. Revvity, Inc.
  • 19.29. Seegene Inc.
  • 19.30. Siemens Healthineers
  • 19.31. T2 Biosystems, Inc.
  • 19.32. Thermo Fisher Scientific Inc.
  • 19.33. Xiamen Bioendo Technology Co., Ltd.
  • 19.34. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LIQUID BROTH CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SOLID MEDIA CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MALDI TOF MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ION TORRENT SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CONVENTIONAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOPHYTOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MUCORMYCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INVASIVE MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC MYCOSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH USE ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 234. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 270. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 282. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 285. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES FU